OUTCOMES FOLLOWING FIRST-LINE IMMUNOTHERAPY WITH OR WITHOUT CHEMOTHERAPY STRATIFIED BY KRAS MUTATIONAL STATUS - A REAL WORLD ANALYSIS IN PATIENTS WITH ADVANCED NSCLC

被引：0

作者：

Aggarwal, Charu ^{[1
]}

Nimeiri, Halla ^{[2
]}

Chen, James ^{[2
]}

Huerga, Iker ^{[2
,3
]}

Horn, Leora ^{[3
]}

Trunova, Nataliya ^{[3
]}

Patel, Jyoti ^{[4
,5
]}

机构：

[1] Univ Penn, Philadelphia, PA USA

[2] Tempus, Chicago, IL USA

[3] AstraZeneca, Chicago, IL USA

[4] Northwestern Univ, Chicago, IL USA

[5] Robert H Lurie Comprehens Canc Cent, Chicago, IL USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.1403

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1403

引用

页码：A1458 / A1458

页数：1

共 50 条

[1] Real World Efficacy of First-Line Immunotherapy plus /Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics
Akerley, W.
Halawani, H.
Schaefer, E.
Page, R.
Ghabach, B.
Evans, J.
Shunyakov, L.
Oubre, D.
Veatch, A.
Akulian, J.
Velcheti, V.
Pitcher, T.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S325 - S325
[2] Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.
Nakajima, Erica C.
Ren, Yi
Vallejo, Jonathon Joseph
Akinboro, Oladimeji
Mishra-Kalyani, Pallavi Shruti
Larkins, Erin A.
Drezner, Nicole Lauren
Tang, Shenghui
Pazdur, Richard
Beaver, Julia A.
Singh, Harpreet
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Prognostic Impact of KRAS Mutational Status in Patients with Advanced Lung Adenocarcinoma Receiving First-Line Cytotoxic Chemotherapy
Desai, Arpita
He, Xiangyun
Gandhi, Shipra
Wang, Chong
Meagher, Alison
Dy, Grace K.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S421 - S421
[4] Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
Pelicon, Veronika
Cufer, Tanja
Knez, Lea
FRONTIERS IN ONCOLOGY, 2023, 13
[5] Clinical characteristics of KRAS mutations in NSCLC and their impact on outcomes to first-line chemotherapy
Butaney, Mohit
Porter, Jennifer
Lindeman, Neal Ian
Janne, Pasi A.
Rabin, Michael S.
Marcoux, J. Paul
Johnson, Bruce E.
Jackman, David Michael
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[6] Real World Report of Clinical Outcomes of Bevacizumab in First-Line or Later-Line Treatment for Patients with Advanced NSCLC
Wang, Y.
Hao, X.
Zhu, Y.
Hu, X.
Wang, H.
Liu, Y.
Mu, Y.
Li, J.
Wen, Y.
Wang, Y.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2078 - S2079
[7] Outcomes of Immunotherapy Versus Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-Analysis of Randomized Clinical Trials
Ponvilawan, Ben
Sharma, Parth
Mahadevia, Himil
Subramanian, Janakiraman
Bansal, Dhruv
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (09) : E90 - E93
[8] Outcomes of Immunotherapy vs Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-analysis of Randomized Clinical Trials
Ponvilawan, B.
Sharma, P.
Mahadevia, H.
Qasim, H.
Subramanian, J.
Bansal, D.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S627 - S627
[9] US real-world immunotherapy-based treatment patterns and clinical outcomes of advanced NSCLC (aNSCLC) patients in the first-line setting
Bittoni, M. A.
Divan, H. A.
Krishna, A.
Gosset, S.
Carbone, D. P.
ANNALS OF ONCOLOGY, 2021, 32 : S1416 - S1416
[10] Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy
Mouritzen, Mette T.
Carus, Andreas
Ladekarl, Morten
Meldgaard, Peter
Nielsen, Anders W. M.
Livbjerg, Anna
Larsen, Jacob W.
Skuladottir, Halla
Kristiansen, Charlotte
Wedervang, Kim
Schytte, Tine
Hansen, Karin H.
Ostby, Anne-Cathrine
Frank, Malene S.
Lauritsen, Jakob
Sorensen, Jens B.
Langer, Seppo W.
Persson, Gitte F.
Andersen, Jon L.
Frary, Johanna M. C.
Drivsholm, Lars B.
Vesteghem, Charles
Christensen, Heidi S.
Bjornhart, Birgitte
Pohl, Mette
CANCERS, 2021, 13 (19)

← 1 2 3 4 5 →